RenovoRx Advances TAMP™ into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP Trial

What happened

RenovoRx announced that the first patient has enrolled in PRISM-TAMP, an investigator-initiated trial (IIT) sponsored by the University of Vermont (UVM) to evaluate intra-arterial gemcitabine delivered via RenovoCath using the Trans-Arterial Micro-Perfusion (TAMP) platform as neoadjuvant therapy before surgery in patients with borderline Pancreatic Ductal Adenocarcinoma (PDAC). The company said a second patient was progressing toward treatment one week after the IIT began. The study is registered on ClinicalTrials.gov under NCT07477418 and UVM plans to enroll approximately 10 patients.

Sources: S1

Trial focus and design details reported

According to the release, PRISM-TAMP's primary focus is to assess PDAC tumor regression, the impact on intraoperative surgical margins following neoadjuvant treatment, and overall safety and tolerability. The IIT will evaluate RenovoRx's intra-arterial gemcitabine delivered via RenovoCath (IAG) in the neoadjuvant setting for borderline resectable pancreatic cancer, where tumors involve nearby blood vessels and pre-surgical treatment can affect resectability.

Sources: S1

Context within RenovoRx development and commercial activity

RenovoRx described PRISM-TAMP as the first RenovoRx-supported IIT to advance to patient enrollment and positioned the study alongside its ongoing Phase III TIGeR-PaC trial. The company stated it is actively commercializing RenovoCath and reported RenovoCath sales of approximately $1.1 million for 2025 along with record quarterly revenue of $909,000 in the second quarter of 2026. The company also said it achieved full enrollment in the TIGeR-PaC trial in August 2026 with topline data expected in the second half of 2027.

Sources: S1

Why this may matter (inference)

An IIT testing localized intra-arterial delivery of gemcitabine prior to surgery could provide data on local tumor response and surgical margin outcomes in borderline resectable PDAC, endpoints the release identifies as primary. The company frames IITs as capital-efficient ways for independent investigators to generate safety and tolerability data for new TAMP applications while RenovoRx continues its Phase III program.

Sources: S1

What remains uncertain

• The report is a company press release; study findings and clinical outcomes from PRISM-TAMP are not presented in this release and have not been independently verified.
• PRISM-TAMP is an investigator-initiated trial sponsored by the University of Vermont; forward-looking timing and enrollment projections in the release are subject to the limitations and risks the company describes in its cautionary statements.